Anthelmintic drugs market seen reaching $4.32 billion by 2030

By AI, Created 11:01 AM UTC, May 20, 2026, /AGP/ – The global anthelmintic drugs market is projected to grow from $3.34 billion in 2025 to $4.32 billion by 2030 as parasitic infections remain widespread and treatment use expands across human and veterinary care. North America led in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Anthelmintic drugs are a core treatment for parasitic worm infections in people and animals, so market growth tracks ongoing public health need. - Rising infection rates, wider veterinary use and broader access through retail and online pharmacies are helping expand demand. - The market outlook points to continued investment in new compounds, combination therapies and parasite-control programs.

What happened: - The Business Research Company released a 2026 report on the global anthelmintic drugs market on May 7, 2026. - The report pegs the market at $3.34 billion in 2025 and forecasts $3.53 billion in 2026. - The report projects the market will reach $4.32 billion by 2030. - The report says the market will grow at a 5.5% CAGR from 2025 to 2026 and 5.2% through 2030. - The company defines anthelmintic drugs as medicines that kill parasitic worms or stop them from reproducing. - The medicines are used against roundworm, tapeworm and hookworm infections.

The details: - Historical growth has been supported by widespread parasitic infections, limited advanced treatment options and continued reliance on traditional drug types. - Public awareness of helminth infections and expansion of hospital and clinic facilities also contributed to growth. - Future growth is expected to come from new anthelmintic compounds and greater use of combination therapies. - Veterinary and livestock demand is projected to increase over the forecast period. - Online and retail pharmacy distribution is expected to widen access. - Government-led parasite control initiatives are also listed as a growth driver. - The report highlights rising prevalence of helminth infections in humans and animals as a major trend. - The report expects greater acceptance of oral and injectable anthelmintic forms. - Broad-spectrum and combination treatments are expected to gain more focus. - The report says North America was the largest market in 2025. - The report says Asia-Pacific will be the fastest-growing region through 2030. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The source includes a free sample report link: Download the sample. - The source also includes the full report link: View the full report.

Between the lines: - The market case is tied less to one product cycle and more to persistent disease burden, which makes demand relatively resilient. - The emphasis on veterinary and livestock applications suggests growth is coming from both human health and animal health markets. - The regional split signals mature demand in North America and faster expansion in markets where healthcare spending and infection rates are rising. - The CDC reported 990 U.S. cases of cyclosporiasis as of Sept. 16, 2025, underscoring continued parasitic-disease monitoring needs.

What’s next: - The market will likely see more competition around broad-spectrum and combination therapies. - Growth may accelerate if new compounds move into wider use and parasite-control initiatives expand. - Distribution through pharmacies and online channels should continue to broaden access through 2030.

The bottom line: - Anthelmintic drugs are on a steady growth path, powered by persistent parasitic infections and rising use in both human and veterinary care.